NextMeds vs Alloy
Two services that charge for the relationship, one inside the price and one outside it.
NextMeds
Editorial
$129/mo
NextMeds sells its GLP-1 treatment as a membership, and the membership price is the whole price: $129 a month for compounded semaglutide and $179 for compounded tirzepatide. Telehealth visits, a care coach, a dietitian and shipping sit inside it. Both rates are described as the same at every dose, and a promotion advertising $100 a month runs under a countdown timer beside it.
Pick it for: Readers who want the bundled figure with nothing owed beside it
Alloy
Editorial
$169/mo
Alloy charges $70 a month for compounded semaglutide, $100 for compounded tirzepatide and $115 for compounded liraglutide, and a $99 monthly care fee alongside each of them. That makes the figures a reader actually pays $169, $199 and $214. Branded semaglutide starts at $199 for the medication, or $298 with the fee.
Pick it for: Readers comparing Alloy's medication rate specifically
Our verdict
NextMeds' figure is the membership and bundles the service into it. Alloy's figure is the medication with a required fee alongside. The difference shows up on the first statement, not on the pricing page.
What actually separates them
NextMeds and Alloy state different things about published price. Everything else they publish, they publish the same way.
Alloy costs $40 more than NextMeds — 31% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,548 at NextMeds against $2,028 at Alloy — a difference of $480.
| NextMeds | Alloy | |
|---|---|---|
| Published price | $129/mo | $169/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.